Daisaikoto Inhibits Pancreatic Lipase Activity and Decreases Serum Triglyceride Levels in Mice

Daisaikoto Extract, a Kampo medicine listed in the Japanese pharmacopoeia 17th edition, is clinically used to treat obesity and related symptoms. Lipid metabolism is closely related to obesity, and pancreatic lipase inhibitors are therefore regarded as effective for the treatment of obesity. Although Daisaikoto has shown promise in the treatment of obesity, its mechanism of action has yet to be elucidated. In the present study, we found that Daisaikoto extract inhibits pancreatic lipase activity in a dose-dependent manner and decreases serum triglyceride levels in mice. To determine the crude drugs responsible for lipase inhibition, 8 variants of Daisaikoto extract without one crude drug were prepared and evaluated for lipase inhibitory activity. The lipase inhibitory activity of the Daisaikoto extract was reduced by excluding Scutellariae Radix (SR), which was found to inhibit lipase activity with an IC50 value of 1.70 mg/mL. In conclusion, Daisaikoto represents a natural medicine, in particular SR, capable of inhibiting pancreatic lipase and lipid absorption.